Last updated on February 2018

Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age


Brief description of study

Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes.Primary infection is manifested as varicella (chickenpox), whereas reactivation of latent VZV results in a localized eruption known as herpes zoster. More than 99.6% of people 40 years of age orolder had evidence of previous VZV infection. This study plans to have 30000 adults 40 years of age or older involoved in a randomized, double-blind, placebo-controlled trial of an investigational live attenuated varicella-zoster virus vaccine. The investigational vaccines are produced by Changchun Changsheng biotechnology co. LTD. The incidence of herpes zoster and the severity, and duration of the associated pain and discomfort were measured after the vaccination. And the safety of the varicella-zoster virus vaccine is also evaluated.

Clinical Study Identifier: NCT03314103

Contact Investigators or Research Sites near you

Start Over

Hongqin Deng, MD

Hunan Provincial Center for Disease Control and Prevention
Loudi, China
  Connect »

Feng-Cai Zhu, MSc

Jiangsu Province Centers for Disease Control and Prevention
Nanjing, China
  Connect »

Zhiping Chen, MD

Zhejiang Provincial Center for Disease Control and Prevention
Hanzhou, China
  Connect »